ENVIRONMENTAL EXPOSURE TO FUNCTION OF LUNG EPITHELIAL STEM CELL BIOLOGY
Dr Clare Weeden
Laboratory Head
The Walter and Eliza Hall Institute of Medical Research (WEHI)
Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | March 2025
Dr Clare Weeden has recently commenced as a Laboratory Head at WEHI in 2025, supported by the CSL Centenary Fellowship.
Dr Weeden specialises in lung epithelial cell biology in the context of homeostasis, inflammation, and lung cancer, particularly in people who don’t smoke. Her work endeavours to understand how past environmental exposures shape the responses of lung cells and the molecular mechanisms underlying this cellular recall, with the aim to develop novel early detection strategies for lung disease.
Dr Weeden completed her PhD studying lung squamous cell carcinoma initiation and treatment with Professor Marie-Liesse Asselin-Labat at WEHI, where she discovered distinct DNA repair abilities in lung stem cells that enabled their susceptibility to cancer, published in PLOS Biology.
Dr Weeden conducted postdoctoral research at WEHI and found that the pre-existing lung immune microenvironment had lasting effects on tumour immunogenicity and response to immunotherapy, published in Cancer Cell. She then continued her research on early tumour biology in Professor Charles Swanton’s laboratory at the Francis Crick Institute, London, where she was part of a team discovery that air pollution triggers inflammatory signalling in the lung that awakens previously dormant cells to initiate lung cancers in people who don’t smoke, published in Nature.
Dr Weeden is the past recipient of prestigious fellowships (Marie Sklodowska Curie Actions, Lung Foundation Australia Deep Manchanda Early Career Fellowship), research grants (Cancer Research UK, Mark Foundation, Cure Cancer/Cancer Australia) and has published 36 research publications with over 1000 citations.
Source: supplied
-
Biostatistics in Clinical Trials
As a biostatistician working in research and clinical settings, Kate Francis plays a vital role in ensuring all projects adhere to best practice guidelines and are transparently reported. She has served as the lead statistician for the analysis of clinical trials across a broad range of subject areas, including neonatal resuscitation, BCG for allergy and infection, convulsive status epilepticus and her work has been published in the top journals such as The New England Journal of Medicine, JAMA, and The Lancet. Most recently she was awarded the 2025 Excellence in Trial Statistics Award for her work on the PLUSS trial.
-
Applying nanotechnology to chronic pain management
Dr Felicity Han is a Research Fellow and Leader in Pain Relief Innovation, at the Australian Institute for Bioengineering and Nanotechnology in the University of Queensland. Dr Han’s research interests sit at the interface of drug delivery and the pain field. Her overarching research goal is to improve the quality of day to day life of patients suffering from chronic pain, by applying nanotechnology to the development of novel highly effective pain-killer products for improving chronic pain management.
-
Role of Community Paramedicine in Non-Emergency Presentations
Dr Robbie King is a Lecturer in paramedicine and researcher at the Australian Catholic University (ACU) Brisbane. He also continues to provide clinical care as a registered paramedic for community members served by a jurisdictional ambulance service. Dr King has gained significant experience working in an advanced practice, community paramedic style role, holding expert clinical insight into the nuances of paramedic-led community-based healthcare for non-emergency presentations. This often involves adopting a biopsychosocial approach, rather than following the biomedical model more associated with emergency medicine and paramedic culture.
